HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Anil Harrison, Speaker at Diabetes Conference
Midwestern University, United States
Title : Evaluating the severity of acute pancreatitis in type 2 diabetes patients treated with incretin-based therapies versus insulin: A multicenter retrospective analysis using APACHE II

Abstract:

This multicenter retrospective study investigates whether incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) influence the severity of acute pancreatitis compared to insulin in patients with type 2 diabetes mellitus. Using the APACHE II scoring system as a validated predictor of severity and ICU-level outcomes, we analyzed 192 patient records from three institutions between 2017–2022. Patients were stratified into two cohorts: those on incretin-based therapies and those on basal/bolus insulin therapy. Findings demonstrated no statistically significant difference in APACHE II scores between the two groups; however, patients on incretin-based agents showed a modest trend toward lower ICU admission rates and reduced length of stay. These results suggest that incretin-based therapies are not associated with worse pancreatitis severity and may, in select populations, be a safer long-term glycemic option with pancreatic tolerability. Additional prospective research is warranted to further validate these findings and explore potential protective mechanisms.

Biography:

Dr. Anil Harrison is Chair of Internal Medicine at Midwestern University Arizona College of Osteopathic Medicine in Glendale, Arizona. He previously served as Program Director at HCA Florida West in Pensacola, where this study originated. With a longstanding commitment to clinical research, medical education, and mentoring, Dr. Harrison has authored multiple studies focused on cardiovascular and metabolic disease outcomes.

Watsapp